Conatus Pharmaceuticals Inc. Extends Liver Disease Reach With Phase 2 Nafld/Nash Trial
3/3/2014 8:59:11 AM
SAN DIEGO, March 3, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH).
Help employers find you! Check out all the jobs and post your resume.
comments powered by